by I. Edwards
The load-loss drug Wegovy might decrease the danger of coronary heart assault, stroke or loss of life greater than comparable drugs, in line with new analysis from its maker, Novo Nordisk.
In a examine of greater than 21,000 sufferers with weight problems and coronary heart illness however no diabetes, these taking Wegovy—which incorporates the lively ingredient semaglutide—noticed a 57% better discount in heart-related dangers in comparison with folks taking tirzepatide, the ingredient in Eli Lilly’s weight-loss medication Mounjaro and Zepbound.
The findings had been introduced at a medical convention and haven’t but been peer-reviewed or printed. As such, they need to be thought to be preliminary.
The true-world examine checked out medical data somewhat than outcomes from a managed scientific trial.
Sufferers taking 2.4 mg of Wegovy had 15 cardiovascular occasions—about 0.1% of members—in contrast with 39 occasions (0.4%) amongst these taking tirzepatide when therapy lasted greater than 30 days, the examine discovered.
Even when researchers included sufferers who paused their drugs for greater than 30 days, Wegovy customers nonetheless noticed a 29% decrease danger of coronary heart assault, stroke or loss of life in contrast with these utilizing tirzepatide.
The outcomes had been introduced Sunday on the European Society of Cardiology Congress in Madrid.
As of Monday, Eli Lilly had not but responded to the findings, The Wall Avenue Journal mentioned.
Extra info:
The Cleveland Clinic has extra on GLP-1 agonists.
Quotation:
Wegovy linked to decrease coronary heart dangers than comparable medication, examine suggests (2025, September 3)
retrieved 4 September 2025
from https://medicalxpress.com/information/2025-09-wegovy-linked-heart-similar-drugs.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
